查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1728102

臨床前 CRO 市場 - 全球產業規模、佔有率、趨勢、機會和預測（按服務、按模型類型、按最終用途行業、按地區和競爭細分，2020-2030 年預測）

Preclinical CRO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service, By Model Type, By End-Use Industry, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球臨床前 CRO 市場價值為 62.4 億美元，預計到 2030 年將達到 101.5 億美元，預測期內複合年成長率為 8.45%。該市場透過提供支援製藥、生物技術和醫療器材公司臨床前研究活動的基本服務，在藥物開發生態系統中發揮著至關重要的作用。臨床前 CRO 提供一系列服務，包括生物分析、毒理學、安全藥理學和化合物管理，幫助客戶滿足監管要求，同時提高效率和成本效益。隨著公司尋求簡化營運並專注於核心競爭力，市場正受益於早期研究外包的增加。藥物研發力度的加大、研究模型的技術進步以及對專業科學知識的需求進一步推動了各地區市場的成長。

市場概覽
預測期 2026-2030
2024年市場規模 62.4億美元
2030年市場規模 101.5億美元
2025-2030 年複合年成長率 8.45%
成長最快的領域 患者來源的類器官（PDO）模型
最大的市場 北美洲

關鍵市場促進因素

外包趨勢日益增強推動市場成長

主要市場挑戰

法規遵從和品質保證

主要市場趨勢

虛擬審判數量的增加

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球臨床前CRO市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按服務（生物分析和 DMPK 研究、毒理學測試、化合物管理、化學、安全藥理學、其他）
    • 依模型類型（患者來源的類器官 (PDO) 模型、患者來源的異種移植模型）
    • 依最終用途產業（生物製藥公司、政府和學術機構、醫療器材公司）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美臨床前CRO市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲臨床前CRO市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太臨床前CRO市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美臨床前CRO市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲臨床前 CRO 市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章： 大環境分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Eurofins Scientific SE
  • PRA Health Sciences, Inc.
  • Wuxi AppTec
  • Medpace, Inc.
  • Charles River Laboratories International, Inc.
  • PPD, Inc.
  • SGA SA
  • Intertek Group Plc
  • LABCORP, Inc.
  • Crown Bioscience Inc

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 17068

The Global Preclinical CRO Market was valued at USD 6.24 billion in 2024 and is projected to reach USD 10.15 billion by 2030, growing at a CAGR of 8.45% during the forecast period. This market plays a crucial role in the drug development ecosystem by providing essential services that support pharmaceutical, biotechnology, and medical device companies in their preclinical research activities. Preclinical CROs offer a range of services including bioanalysis, toxicology, safety pharmacology, and compound management, helping clients meet regulatory requirements while improving efficiency and cost-effectiveness. The market is benefiting from the increased outsourcing of early-stage research, as companies seek to streamline operations and focus on core competencies. The rise in drug discovery efforts, technological advancements in research models, and demand for specialized scientific expertise are further driving market growth across regions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.24 Billion
Market Size 2030USD 10.15 Billion
CAGR 2025-20308.45%
Fastest Growing SegmentPatient Derived Organoid (PDO) Model
Largest MarketNorth America

Key Market Drivers

Increasing Outsourcing Trends Drives the Market Growth

A major growth driver for the Global Preclinical CRO Market is the increasing trend of outsourcing among pharmaceutical and biotechnology companies. By outsourcing preclinical R&D activities to specialized CROs, companies are able to significantly reduce costs associated with facility maintenance, personnel, and equipment. CROs offer advanced infrastructure and expert staff, allowing sponsors to accelerate timelines while ensuring regulatory compliance. This model also provides scalability, enabling companies to adapt to changing project demands without major internal investments. Moreover, CROs grant access to cutting-edge technologies and methodologies, helping clients improve research outcomes while focusing internal resources on clinical trials, regulatory strategies, and commercialization. As the demand for efficient and flexible research solutions continues to rise, outsourcing remains a preferred strategy, bolstering the growth of the preclinical CRO sector globally.

Key Market Challenges

Regulatory Compliance and Quality Assurance

The Global Preclinical CRO Market faces considerable challenges due to complex regulatory requirements and the need for strict quality assurance. Regulatory bodies such as the FDA and EMA impose rigorous standards that CROs must meet to ensure that studies are conducted ethically, accurately, and in compliance with international guidelines. Navigating diverse and evolving regulations across multiple geographies adds complexity, particularly for CROs working with global clients. Maintaining compliance requires ongoing investment in specialized personnel, documentation systems, quality audits, and training, which can strain operational resources. Delays or errors in regulatory adherence may lead to costly project setbacks or non-approval of drug candidates in later stages, underscoring the critical need for continuous regulatory vigilance and operational excellence in the CRO landscape.

Key Market Trends

Increase in the Number of Virtual Trials

A significant trend transforming the Global Preclinical CRO Market is the growing adoption of virtual or decentralized clinical trials, which leverage digital tools to collect patient data remotely. Although primarily impacting clinical phases, this trend is influencing preclinical CROs to expand their technological capabilities and align with integrated drug development models. CROs are now incorporating wearable devices, mobile apps, and telehealth platforms to facilitate remote monitoring and data collection, enabling smoother transitions from preclinical to clinical stages. These digital advancements enhance patient recruitment, diversify participation, and improve data accuracy. As a result, CROs are partnering with tech providers and investing in secure data infrastructure to support virtual research models, thereby optimizing trial efficiency and reducing dependency on traditional site-based models.

Key Market Players

  • Eurofins Scientific SE
  • PRA Health Sciences, Inc.
  • Wuxi AppTec
  • Medpace, Inc.
  • Charles River Laboratories International, Inc.
  • PPD, Inc.
  • SGA SA
  • Intertek Group Plc
  • LABCORP Inc.
  • Crown Bioscience Inc

Report Scope:

In this report, the Global Preclinical CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preclinical CRO Market, By Service:

  • Bioanalysis and DMPK Studies
  • Toxicology Testing
  • Compound Management
  • Chemistry
  • Safety Pharmacology
  • Others

Preclinical CRO Market, By Model Type:

  • Patient Derived Organoid (PDO) Model
  • Patient Derived Xenograft Model

Preclinical CRO Market, By End User Industry:

  • Biopharmaceutical Companies
  • Government and Academic Institutes
  • Medical Device Companies

Preclinical CRO Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preclinical CRO Market.

Available Customizations:

Global Preclinical CRO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preclinical CRO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Service (Bioanalysis and DMPK Studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology, Others)
    • 5.2.2. By Model Type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model)
    • 5.2.3. By End-Use Industry (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Preclinical CRO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Service
    • 6.2.2. By Model Type
    • 6.2.3. By End-Use Industry
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Preclinical CRO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Service
        • 6.3.1.2.2. By Model Type
        • 6.3.1.2.3. By End-Use Industry
    • 6.3.2. Mexico Preclinical CRO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Service
        • 6.3.2.2.2. By Model Type
        • 6.3.2.2.3. By End-Use Industry
    • 6.3.3. Canada Preclinical CRO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Service
        • 6.3.3.2.2. By Model Type
        • 6.3.3.2.3. By End-Use Industry

7. Europe Preclinical CRO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Service
    • 7.2.2. By Model Type
    • 7.2.3. By End-Use Industry
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Preclinical CRO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Service
        • 7.3.1.2.2. By Model Type
        • 7.3.1.2.3. By End-Use Industry
    • 7.3.2. Germany Preclinical CRO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Service
        • 7.3.2.2.2. By Model Type
        • 7.3.2.2.3. By End-Use Industry
    • 7.3.3. United Kingdom Preclinical CRO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Service
        • 7.3.3.2.2. By Model Type
        • 7.3.3.2.3. By End-Use Industry
    • 7.3.4. Italy Preclinical CRO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Service
        • 7.3.4.2.2. By Model Type
        • 7.3.4.2.3. By End-Use Industry
    • 7.3.5. Spain Preclinical CRO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Service
        • 7.3.5.2.2. By Model Type
        • 7.3.5.2.3. By End-Use Industry

8. Asia-Pacific Preclinical CRO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Service
    • 8.2.2. By Model Type
    • 8.2.3. By End-Use Industry
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Preclinical CRO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Service
        • 8.3.1.2.2. By Model Type
        • 8.3.1.2.3. By End-Use Industry
    • 8.3.2. India Preclinical CRO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Service
        • 8.3.2.2.2. By Model Type
        • 8.3.2.2.3. By End-Use Industry
    • 8.3.3. South Korea Preclinical CRO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Service
        • 8.3.3.2.2. By Model Type
        • 8.3.3.2.3. By End-Use Industry
    • 8.3.4. Japan Preclinical CRO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Service
        • 8.3.4.2.2. By Model Type
        • 8.3.4.2.3. By End-Use Industry
    • 8.3.5. Australia Preclinical CRO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Service
        • 8.3.5.2.2. By Model Type
        • 8.3.5.2.3. By End-Use Industry

9. South America Preclinical CRO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Service
    • 9.2.2. By Model Type
    • 9.2.3. By End-Use Industry
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Preclinical CRO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Service
        • 9.3.1.2.2. By Model Type
        • 9.3.1.2.3. By End-Use Industry
    • 9.3.2. Argentina Preclinical CRO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Service
        • 9.3.2.2.2. By Model Type
        • 9.3.2.2.3. By End-Use Industry
    • 9.3.3. Colombia Preclinical CRO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Service
        • 9.3.3.2.2. By Model Type
        • 9.3.3.2.3. By End-Use Industry

10. Middle East and Africa Preclinical CRO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Service
    • 10.2.2. By Model Type
    • 10.2.3. By End-Use Industry
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Preclinical CRO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Service
        • 10.3.1.2.2. By Model Type
        • 10.3.1.2.3. By End-Use Industry
    • 10.3.2. Saudi Arabia Preclinical CRO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Service
        • 10.3.2.2.2. By Model Type
        • 10.3.2.2.3. By End-Use Industry
    • 10.3.3. UAE Preclinical CRO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Service
        • 10.3.3.2.2. By Model Type
        • 10.3.3.2.3. By End-Use Industry

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Eurofins Scientific SE
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. PRA Health Sciences, Inc.
  • 15.3. Wuxi AppTec
  • 15.4. Medpace, Inc.
  • 15.5. Charles River Laboratories International, Inc.
  • 15.6. PPD, Inc.
  • 15.7. SGA SA
  • 15.8. Intertek Group Plc
  • 15.9. LABCORP, Inc.
  • 15.10. Crown Bioscience Inc

16. Strategic Recommendations

17. About Us & Disclaimer